|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Operating expenses | |
| Research and development (Note 19) | |
| General and administrative (Note 19) | |
| Total operating expenses | |
| Interest income | |
| Unrealized loss on warrant derivative (Note 15) | |
| Foreign exchange loss (gain) | |
| Net loss | |
| Comprehensive loss | |
| Basic net loss per share | |
| Diluted net loss per share | |
| Weighted average Common Shares outstanding, Basic (in shares) | |
| Weighted average Common Shares outstanding, Diluted (in shares) |
Loading...
